|Akebia Therapeutics Inc., of Cambridge, Mass.||Riona (ferric citrate hydrate)||Iron-based phosphate binder||Iron deficiency anemia||Collaboration partner Japan Tobacco Inc. received PMDA approval to treat adults in Japan for additional indication|
|Ascentage Pharma Group International, of Suzhou, China||Olverembatinib (HQP-1351)||BCR-ABL tyrosine kinase inhibitor||Chronic myeloid leukemia||Center for Drug Evaluation of China's NMPA recommended breakthrough therapy designation for agent advanced by wholly owned subsidiary Guangzhou Healthquest Pharma Co. Ltd. to treat chronic-phase disease that is resistant/intolerant to first- and second-generation TKIs|
|Berg LLC, of Framingham, Mass.||BPM-31510||Increases mitochondrial-centric oxidative stress||Glioblastoma multiforme||FDA cleared the phase II study testing BPM-31510 as a neo-adjuvant|
|Enterome SA, of Paris||EO-2463||Microbiome-derived multipeptide-based vaccine||Non-Hodgkin B-cell lymphoma||FDA cleared IND for phase I/II trial to evaluate study drug with standard of care in 60 participants with follicular or marginal zone lymphoma|
|Horizon Therapeutics plc, of Dublin||Uplizna (inebilizumab-cdon)||B-lymphocyte antigen CD19 inhibitor||Neuromyelitis optica spectrum disorder||Partner Mitsubishi Tanabe Pharma Corp. received manufacturing and marketing approval from Japan's MHLW to prevent disease relapses|
|Reneo Pharmaceuticals Inc., of San Diego||REN-001||PPAR delta agonist||Primary mitochondrial myopathy||FDA granted fast track designation|
|Russian Direct Investment Fund (RDIF) and Chemrar Group, both of Moscow||Avifavir (favipiravir)||RNA polymerase inhibitor||COVID-19 infection||National Agency of Drug and Food Control of Indonesia approved drug|
For more information about individual companies and/or products, see Cortellis.